Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
29,927,164
-
Shares change
-
-693,985
-
Total reported value, excl. options
-
$290,480,832
-
Value change
-
-$6,832,587
-
Put/Call ratio
-
44%
-
Number of buys
-
40
-
Number of sells
-
-34
-
Price
-
$9.69
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q2 2022
108 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q2 2022.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29,927,164 shares
.
Largest 10 shareholders include BlackRock Inc. (3,535,357 shares), PICTET ASSET MANAGEMENT SA (3,531,802 shares), VANGUARD GROUP INC (2,927,981 shares), HHLR ADVISORS, LTD. (2,920,023 shares), BAKER BROS. ADVISORS LP (2,799,577 shares), Hudson Bay Capital Management LP (1,375,000 shares), GREAT POINT PARTNERS LLC (1,204,028 shares), ArrowMark Colorado Holdings LLC (1,151,137 shares), RICE HALL JAMES & ASSOCIATES, LLC (814,673 shares), and Opaleye Management Inc. (814,250 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.